dc.contributor.author | Jain, AK | |
dc.contributor.author | Bataille, CJR | |
dc.contributor.author | Milhas, S | |
dc.contributor.author | Miller, A | |
dc.contributor.author | Zhang, J | |
dc.contributor.author | Rabbitts, TH | |
dc.date.accessioned | 2021-01-11T09:16:54Z | |
dc.date.issued | 2020-12-21 | |
dc.identifier | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000602578800027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9 | |
dc.identifier.citation | ACS APPLIED BIO MATERIALS, 2020, 3 (12), pp. 8481 - 8495 (15) | |
dc.identifier.issn | 2576-6422 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4271 | |
dc.identifier.doi | 10.1021/acsabm.0c00857 | |
dc.description.abstract | Macromolecules such as antibodies and antibody fragments have been reported to interfere with intracellular targets, but their use is limited to delivery systems where expression is achieved from vectors such as plasmids or viruses. We have developed PEGylated nanoparticles of poly-lactic acid (PLA), including the cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), which are functionalized with monoclonal anti-CD7, anti-CD53, or anti-GPR56 antibodies for receptor-mediated endocytic delivery into T-cell leukemia cell lines. Incorporation of DOTAP as the lipid component of the PLA nanoparticles enhanced the release of the immuno-nanoparticles from the endosomes into the cytosol compared to nanoparticles made from PLA alone. Systemic delivery of these anti-CD7 immuno-nanoparticles into humanized CD7 transgenic mice resulted in localization in the spleen, enhanced uptake into CD7-expressing splenocytes, and release of low amounts of reporter mRNA for translation. These functionalized polymer lipid nanoparticles are the basis for elaboration and optimization for realizing their potential in therapeutic applications to carry specific macromolecules such as mRNAs for translation into therapeutic proteins that can target intracellular proteins which mediate disease. | |
dc.format.extent | 8481 - 8495 (15) | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER CHEMICAL SOC | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | Science & Technology | |
dc.subject | Technology | |
dc.subject | Nanoscience & Nanotechnology | |
dc.subject | Materials Science, Biomaterials | |
dc.subject | Science & Technology - Other Topics | |
dc.subject | Materials Science | |
dc.subject | mRNA delivery | |
dc.subject | cytosolic delivery | |
dc.subject | polymer nanoparticles | |
dc.subject | PLA-PEG | |
dc.subject | macromolecule delivery | |
dc.subject | CD7 | |
dc.subject | T-ALL | |
dc.subject | MODIFIED MESSENGER-RNA | |
dc.subject | PEG-PLA NANOPARTICLES | |
dc.subject | NUCLEOSIDE MODIFICATIONS | |
dc.subject | PROTEIN INTERACTIONS | |
dc.subject | ANTIBODY FRAGMENTS | |
dc.subject | CATIONIC LIPIDS | |
dc.subject | IN-VITRO | |
dc.subject | GENE | |
dc.subject | CANCER | |
dc.subject | DOMAIN | |
dc.title | Immunopolymer Lipid Nanoparticles for Delivery of Macromolecules to Antigen-Expressing Cells. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-10-29 | |
rioxxterms.versionofrecord | 10.1021/acsabm.0c00857 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2020-12-21 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | ACS APPLIED BIO MATERIALS | |
pubs.declined | 2021-01-11T09:07:24.166+0000 | |
pubs.issue | 12 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics | |
pubs.publication-status | Published | |
pubs.volume | 3 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Chromosomal Translocations and Intracellular Antibody Therapeutics | |
dc.contributor.icrauthor | Rabbitts, Terence | |